JACC. Case reports · 2026
A Very Late Mitral Valve Hypoattenuated Leaflet Thickening With Significant Warfarin Response.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almasri Mariam, Wong Alan, Seshiah Puvi, El-Hangouche Nadia, Bashir Hanad
Аннотация
BACKGROUND: Hypoattenuated leaflet thickening (HALT) represents subclinical leaflet thrombosis in bioprosthetic valves with risk of occurrence peaking at 12 to 24 months after implantation. However, late presentations can occur.
CASE SUMMARY: A 77-year-old woman developed severe mitral stenosis 17 years after receiving a bioprosthetic mitral valve. Cardiac CT revealed extensive hypoattenuated leaflet thrombosis affecting all leaflets. After 3 months of therapeutic warfarin, repeat imaging demonstrated significant HALT resolution, avoiding valve-in-valve intervention.
DISCUSSION: This represents an unusual late HALT presentation, causing bioprosthetic mitral valve dysfunction, which exceeds usual follow-up periods. The significant response to warfarin supports anticoagulation effectiveness and thrombotic etiology.
TAKE-HOME MESSAGES: Since HALT can occur very late after valve replacement, long-term monitoring needs to be considered. Warfarin anticoagulation can effectively resolve HALT even in late presentations, helping to avoid surgical intervention.
CASE SUMMARY: A 77-year-old woman developed severe mitral stenosis 17 years after receiving a bioprosthetic mitral valve. Cardiac CT revealed extensive hypoattenuated leaflet thrombosis affecting all leaflets. After 3 months of therapeutic warfarin, repeat imaging demonstrated significant HALT resolution, avoiding valve-in-valve intervention.
DISCUSSION: This represents an unusual late HALT presentation, causing bioprosthetic mitral valve dysfunction, which exceeds usual follow-up periods. The significant response to warfarin supports anticoagulation effectiveness and thrombotic etiology.
TAKE-HOME MESSAGES: Since HALT can occur very late after valve replacement, long-term monitoring needs to be considered. Warfarin anticoagulation can effectively resolve HALT even in late presentations, helping to avoid surgical intervention.